Description
Description:
Evista is a medication manufactured by Daiichi Sankyo. Each pack contains 28 pills, with each pill containing 60 mg of the active substance Raloxifene. Raloxifene is a selective estrogen receptor modulator (SERM) that is primarily used in the prevention and treatment of osteoporosis in postmenopausal women. It is also indicated for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer.
Active Substance:
Raloxifene is the active substance in Evista. It belongs to the class of medications known as selective estrogen receptor modulators (SERMs). Raloxifene acts by selectively binding to estrogen receptors in certain tissues, thereby mimicking some of the beneficial effects of estrogen without affecting other tissues. This can help prevent bone loss and reduce the risk of fractures in postmenopausal women with osteoporosis.
Indications:
Evista is indicated for the prevention and treatment of osteoporosis in postmenopausal women. It is also indicated for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer. Additionally, Evista may be used off-label for the treatment of other medical conditions, as determined by the prescribing healthcare provider.
Dosage and Administration:
The dosage of Evista and the frequency of administration may vary depending on the patient’s medical condition, age, and response to treatment. It is typically taken orally once daily, with or without food. The recommended dosage for the prevention and treatment of osteoporosis in postmenopausal women is usually 60 mg once daily. The duration of treatment will be determined by the treating physician based on individual patient needs.
Precautions:
Before using Evista, patients should undergo a thorough medical evaluation and discuss their medical history and any pre-existing conditions with their healthcare provider. Evista may interact with certain medications or medical conditions, so it is essential to disclose all relevant information to the healthcare provider. Regular monitoring of bone density and other parameters may be necessary during treatment with Evista.
Side Effects:
Common side effects associated with Evista may include hot flashes, leg cramps, peripheral edema, and joint pain. More serious side effects such as venous thromboembolism, stroke, and increased risk of endometrial cancer may occur less frequently. Patients should report any unusual symptoms or side effects to their healthcare provider promptly.
Conclusion:
Evista, containing the active substance Raloxifene, is a medication used in the prevention and treatment of osteoporosis in postmenopausal women. Manufactured by Daiichi Sankyo, Evista is available in pill form and is typically taken orally once daily. Patients should follow the recommendations of their physician and healthcare team for optimal treatment outcomes and management of potential side effects.
Reviews
There are no reviews yet.